This invention relates to methods of administering compounds containing selenium, selenocysteine, or a selenocysteine peptide to treat, for example, conditions associated with selenium deficiency, or ferroptoptic, parthanototic, and endoplasmic reticulum stress, and/or cancer. The methods of treatment may activate or inhibit (via TFAP2C and Sp1 proteins) the adaptive homeostatic response of the selenome. The compounds may contain a targeting sequence that causes them to be delivered to specific organs and/or tissues. The compounds may be administered, for example, orally, intranasally, intravenously, or by a minimally invasive catheter or BrainPath.

This invention relates to methods of administering compounds containing selenium, selenocysteine, or a selenocysteine peptide to treat, for example, conditions associated with selenium deficiency, or ferroptoptic, parthanototic, and endoplasmic reticulum stress, and/or cancer. The methods of treatment may activate or inhibit (via TFAP2C and Sp1 proteins) the adaptive homeostatic response of the selenome. The compounds may contain a targeting sequence that causes them to be delivered to specific organs and/or tissues. The compounds may be administered, for example, orally, intranasally, intravenously, or by a minimally invasive catheter or BrainPath.

The present invention relates to methods and compositions for modifying mucous membranes. In particular, the present invention relates to treating diseases associated with mucous membranes by changing the intrinsic chemical composition and/or physical features of a target mucous membrane.

The present invention relates to methods and compositions for modifying mucous membranes. In particular, the present invention relates to treating diseases associated with mucous membranes by changing the intrinsic chemical composition and/or physical features of a target mucous membrane.

A method of predicting and treating doxorubicin-resistant cancer including determining expression of Myc-regulated genes and MPST transcription levels. The method further includes classifying the cancer as doxorubicin resistant when either Myc transcription is higher than IMR-32 transcription or MPST transcription levels are above a predetermined amount. The method further includes administering an effective amount of AP39 for ameliorating the doxorubicin-induced cardiotoxicity by combing doxorubicin with AP39.

A method of predicting and treating doxorubicin-resistant cancer including determining expression of Myc-regulated genes and MPST transcription levels. The method further includes classifying the cancer as doxorubicin resistant when either Myc transcription is higher than IMR-32 transcription or MPST transcription levels are above a predetermined amount. The method further includes administering an effective amount of AP39 for ameliorating the doxorubicin-induced cardiotoxicity by combing doxorubicin with AP39.

The present disclosure provides methods of treating and/or preventing cancer in a subject comprising administering to the subject a copper-reduced diet by itself or as a supplement along with a regular diet to create a copper-reduced melieu, maintain a reduced-copper melieu, or both, thereby treating and/or preventing the development of the cancer. Methods also comprise further adding a copper chelator, MEK inhibitor, or combinations thereof.

The present disclosure provides methods of treating and/or preventing cancer in a subject comprising administering to the subject a copper-reduced diet by itself or as a supplement along with a regular diet to create a copper-reduced melieu, maintain a reduced-copper melieu, or both, thereby treating and/or preventing the development of the cancer. Methods also comprise further adding a copper chelator, MEK inhibitor, or combinations thereof.

The present disclosure provides methods of treating and/or preventing cancer in a subject comprising administering to the subject a copper-reduced diet by itself or as a supplement along with a regular diet to create a copper-reduced melieu, maintain a reduced-copper melieu, or both, thereby treating and/or preventing the development of the cancer. Methods also comprise further adding a copper chelator, MEK inhibitor, or combinations thereof.

A nutritional supplement composition, is disclosed. The nutritional supplement composition includes one or more vitamins and mixtures. The one or more vitamins and mixtures are selected from the group consisting of an iron supplement comprising a combination of active ingredients. The active ingredients include carbonyl iron. The active ingredients include vitamin C. The active ingredients include ginger.